ReviewPharmaceuticals (Basel, Switzerland)2020
Atopic Dermatitis as a Multifactorial Skin Disorder. Can the Analysis of Pathophysiological Targets Represent the Winning Therapeutic Strategy?
Review in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study.Dermatology and therapy · 2026Article
- Skin-Immune-Neuro-Gastro-Endocrine (SINGE) System: Lighting the Fire on Atopic Dermatitis Research.Dermatology practical & conceptual · 2025Review
- Article
- Vinpocetine, a phosphodiesterase 1 inhibitor, mitigates atopic dermatitis-like skin inflammation.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2024Article
- TargetingPharmaceutics · 2024Article
- Primary Prevention of Canine Atopic Dermatitis: Breaking the Cycle-A Narrative Review.Veterinary sciences · 2023Review
- Innovative Phospholipid Carriers: A Viable Strategy to Counteract Antimicrobial Resistance.International journal of molecular sciences · 2023Review
- A Wall Fragment ofPharmaceutics · 2023Article
- Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment.International journal of molecular sciences · 2023Article
- Effect of treatments on skin microbiota in patients with atopic dermatitis: a protocol for systematic review.BMJ open · 2022Article
- The new invasive mosquito speciesFrontiers in microbiology · 2022Review
- Novel Insights into the Role of Probiotics in Respiratory Infections, Allergies, Cancer, and Neurological Abnormalities.Diseases (Basel, Switzerland) · 2021Review
- Special Issue "Novel Antibacterial Agents".Pharmaceuticals (Basel, Switzerland) · 2021Article
- Potential Mucosal Irritation Discrimination of Surface Disinfectants Employed against SARS-CoV-2 byBiomedicines · 2021Article
- Molecular epidemiology of Staphylococcus aureus in African children from rural and urban communities with atopic dermatitis.BMC infectious diseases · 2021Article
- The Wound Healing Peptide, AES16-2M, Ameliorates Atopic Dermatitis In Vivo.Molecules (Basel, Switzerland) · 2021Article
- Burden of Disease, Unmet Needs in the Diagnosis and Management of Atopic Dermatitis: An Indian Expert Consensus.Clinical, cosmetic and investigational dermatology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Atopic dermatitis (AD) is a pathological skin condition with complex aetiological mechanisms that are difficult to fully understand. Scientific evidence suggests that of all the causes, the impairment of the skin barrier and cutaneous dysbiosis together with immunological dysfunction can be considered as the two main factors involved in this pathological skin condition. The loss of the skin barrier function is often linked to dysbiosis and immunological dysfunction, with an imbalance in the ratio between the pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.